Biosergen recently announced the completion of treatment for the first cohort of patients in its proof-of-concept trial for its antifungal drug candidate BSG005. Most patients improved significantly, reflecting BSG005’s potential as a life-saving therapy. The next step involves dose escalation for the upcoming cohort. Importantly, between November 18 and 29, shareholders can exercise the warrants TO3, which could add a maximum of approximately SEK 45 million to the company, funding it well through 2025.
Read the interview with CEO Tine Olesen at biostock.se:
https://www.biostock.se/en/2024/11/biosergens-ceo-im-optimistic-that-we-may-cure-patients/
This is a press release from BioStock – Connecting Innovation & Capital. https://www.biostock.se/en/
